Neutral Cipla Ltd for the Target Rs. 1,307 by Motilal Oswal Financial Services Ltd
Cipla gets USFDA nod for albuterol inhaler, strengthening US respiratory play
* Cipla received USFDA approval for the first AB-rated generic of Ventolin HFA (albuterol inhaler), giving it a first-to-market edge with pharmacy-level substitution in the US.
* The broader market size is ~USD1.5b, though the effective opportunity is closer to ~USD500m, with estimated annual sales potential of ~USD100m thanks to limited competition.
* This approval strengthens Cipla’s US respiratory portfolio, a key high-barrier segment, with launch expected in 1HFY27 and gradual scale-up.
* Manufacturing at its Fall River (US) facility improves supply reliability and supports domestic presence while helping offset declining g-Revlimid revenue.
* G-Ventolin would support growth prospects, strengthen its respiratory portfolio and offset the impact of competitive pressure on g-Revlimid. Having said this, we expect moderate 6-8% earnings CAGR over FY26-28. Maintain Neutral with a TP of INR1,307.
USFDA approval for albuterol (Ventolin generic) supports growth in US respiratory franchise
* Cipla has received approval from the USFDA for its albuterol inhaler, the first AB-rated generic of Ventolin HFA (originator: GlaxoSmithKline).
* The company plans to launch the product in 1HFY27, providing a first-tomarket opportunity in the ~USD1.5b albuterol market in the US, with automatic substitution benefits.
* The product will be manufactured at Cipla’s Fall River (US) facility, enhancing supply reliability and supporting a stronger domestic manufacturing footprint.
* The approval strengthens Cipla’s US respiratory franchise, a key focus area with high entry barriers in complex inhalation products, and aligns with its strategy of expanding in margin-accretive complex generics. * This development builds on Cipla’s earlier success following USFDA approval in FY21 for the first AB-rated generic of Proventil HFA, which marked its entry into the US device-based inhalation segment.
* Since then, Cipla has scaled up strongly, supplying 50m+ inhaler units in the US and increasing its market share in the albuterol MDI segment from ~13% (FY24) to ~18% (FY25) and further to ~22% (Dec’25, IQVIA), demonstrating strong execution capabilities.
* The company’s proven track record in scaling up its earlier Albuterol launch indicates that the latest approval is also likely to see effective commercialization and meaningful medium-term contribution.
Ventolin generic approval materially enlarges US respiratory opportunity
* Ventolin HFA is one of the most established short-acting beta agonist (SABA) inhalers globally, generating ~USD2.6b in cumulative revenue over the past five years, supported by its strong brand recall, wide prescription base, and long clinical track record.
* Alongside Proventil HFA and ProAir HFA, Ventolin belongs to the same class of albuterol MDIs. However, differences in fine particle dose, plume characteristics, and excipient profile result in varying patient experience and lung drug delivery, with ProAir and Proventil typically delivering higher lung deposition vs. Ventolin.
* From a market perspective, Ventolin has remained one of the most widely prescribed inhalers despite relatively lower lung delivery efficiency, driven by physician familiarity, absence of certain excipients, and global availability.
* Cipla is now strategically positioned with generics for both Ventolin and Proventil, strengthening its presence across key albuterol inhaler segments. Among Indian peers, Lupin has exposure via its generic version of ProAir.
* This dual presence enhances Cipla’s ability to capture a broader share of the US albuterol inhaler market across molecules and device profiles, supporting sustainable growth in its respiratory portfolio.
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
